← Back to Search

Amino Acid Supplement

Protein Intake for Older Athletes

N/A
Recruiting
Research Sponsored by McGill University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Must not have
Recent history of weight loss or weight gain exceeding 5% of body weight
Uncontrolled hypertension
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7-weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to determine the amount of protein needed by older cyclists after endurance training using a new non-invasive method. The current protein recommendations for athletes may be underestimated, so this study seeks to provide

Who is the study for?
This trial is for male master cyclists aged 35 and above who regularly engage in intense training. Participants should be healthy, without any metabolic disorders that affect nutrition. They must not have dietary restrictions that could impact protein intake.
What is being tested?
The study aims to determine the optimal amount of protein needed after cycling exercises using a method called Indicator Amino Acid Oxidation (IAAO). It seeks to reassess current nutritional guidelines for highly active older adults.
What are the potential side effects?
Since this trial involves dietary intervention with amino acid intake, side effects are minimal but may include digestive discomfort or allergic reactions if participants have unknown sensitivities.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have recently lost or gained more than 5% of my body weight.
Select...
My blood pressure is not controlled by medication.
Select...
I am currently taking anti-inflammatory medications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7-weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7-weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
13CO2 Excretion
Secondary study objectives
L[13C]phenylalanine Oxidation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Masters Level CyclistsExperimental Treatment1 Intervention
Participants are to be randomly assigned varying levels of amino acid intakes ranging between 0.5 to 2.8 g/kg/d
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amino Acid Intake
2016
N/A
~50

Find a Location

Who is running the clinical trial?

McGill UniversityLead Sponsor
414 Previous Clinical Trials
1,015,433 Total Patients Enrolled
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top